Table 5.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1994 to 2003

Recipients with Kidney Transplants

  Year of Transplant
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Transplants 10,646 11,078 11,398 11,701 12,446 12,756 13,611 14,263 14,777 15,134
Tx with Antirejection Treatments 3,361 4,317 5,836 3,442 2,653 2,451 2,378 2,395 2,190 1,992
Antibodies Any in Category 53.4% 32.1% 16.8% 27.2% 36.9% 37.1% 35.5% 37.5% 38.5% 47.7%
ALG 18.7% 5.8% 0.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Atgam/NRATG/NRATS 0.8% 2.3% 3.4% 6.6% 8.1% 6.0% 2.9% 2.5% 2.3% 1.8%
OKT3 43.0% 26.5% 13.9% 21.6% 26.2% 18.8% 14.6% 11.6% 10.8% 8.9%
Thymoglobulin 0.0% 0.0% 0.1% 0.2% 1.0% 7.9% 12.9% 18.0% 23.6% 31.1%
Zenapax 0.0% 0.0% 0.0% 0.2% 3.4% 5.8% 3.4% 2.9% 1.9% 3.2%
Simulect 0.0% 0.0% 0.0% 0.0% 0.3% 1.6% 4.0% 5.0% 3.4% 5.5%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.2% 1.5%
Corticosteroids Any in Category 78.7% 58.0% 38.5% 58.7% 78.7% 78.4% 80.2% 80.2% 79.8% 72.4%
Steroids 78.7% 58.0% 38.5% 58.7% 78.7% 78.4% 80.2% 80.2% 79.8% 72.4%
Antimetabolites Any in Category 0.2% 0.2% 0.3% 0.5% 0.1% 0.1% 0.3% 0.2% 0.1% 0.2%
Cytoxan 0.2% 0.1% 0.2% 0.3% 0.1% 0.1% 0.3% 0.1% 0.1% 0.2%
Methotrexate 0.0% 0.1% 0.1% 0.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of May 2, 2005.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients maybe prescribed more than one drug within the same category.